Retatrutide is an investigational drug that is not FDA-approved and not available at any pharmacy. It is a triple-hormone agonist in Phase 3 trials from Eli Lilly. This page compares what the trial data shows against Ozempic (semaglutide), which is available now. All comparisons are cross-trial — no head-to-head study exists.
Ozempic vs Retatrutide: What to Know
Helpful Products for GLP-1 Treatment
Managing your GLP-1 medication is easier with the right tools:
- Sharps container — Essential for safe needle disposal. A sharps container is required for home use.
- Ginger products — Manage nausea with ginger chews or ginger tea.
- Water bottle — Stay hydrated to reduce side effects. A large water bottle helps you track intake.
- Electrolyte packets — Prevent dehydration. Liquid I.V. packets dissolve easily in water.
GLPSpot may earn from qualifying purchases.
Quick Comparison
| Ozempic | Retatrutide | |
|---|---|---|
| Active drug | Semaglutide | Retatrutide |
| Drug class | GLP-1 agonist | Triple GIP/GLP-1/Glucagon agonist |
| FDA approval | Type 2 diabetes (approved) | Phase 3 trials (not FDA-approved) |
| Dosing | Once weekly injection | Once weekly injection (in trials) |
| Maker | Novo Nordisk | Eli Lilly |
| Status | Available now | Investigational — not available |
| Weight loss | ~10–15% | 28.3% at 80 wks (TRIUMPH-1); 30.3% at 104 wks (BMI ≥35 subset) |
Cross-trial comparison only. These numbers come from separate studies with different populations, durations, and designs. They cannot be directly compared.
How They Work
Ozempic mimics one hormone (GLP-1) that signals fullness and slows digestion.
Retatrutide mimics three hormones:
- GLP-1 — signals fullness
- GIP — boosts the GLP-1 effect
- Glucagon — increases calorie burning
Three signals instead of one. That's the big difference.
Weight Loss Results
From clinical trials (as of May 2026):
- Ozempic: ~10–15% body weight loss
- Retatrutide — TRIUMPH-1 (general obesity): up to 28.3% average body weight loss at 80 weeks on 12 mg; a subset with BMI ≥35 who continued to 104 weeks reached 30.3%
- Retatrutide — TRIUMPH-4 (obesity with knee osteoarthritis): up to 28.7% at 72 weeks
- Retatrutide — TRANSCEND-T2D-1 (type 2 diabetes): up to 16.8% at 40 weeks
The 28.7% figure comes from TRIUMPH-4, a specific trial in people with knee osteoarthritis. The broader general-obesity figure from TRIUMPH-1 is 28.3% at 80 weeks. These are impressive results, but they are from different trials than those that studied Ozempic. No head-to-head trial exists.
Side Effects
Ozempic side effects:
- Nausea (most common)
- Diarrhea or constipation
- Decreased appetite
- Stomach pain
Retatrutide side effects (from trials):
- Nausea
- Decreased appetite
- Increased heart rate (from glucagon component)
- Diarrhea or constipation
- Dysesthesia (tingling or burning sensation) — reported in 20.9% of people at the 12 mg dose in TRIUMPH-1. Most cases were mild and did not cause people to stop the drug.
The glucagon component in Retatrutide may cause a slightly higher heart rate, which is being monitored. Tell your doctor if you have heart rhythm concerns.
Availability
Retatrutide is not yet FDA-approved. Three Phase 3 trials have reported positive results (TRIUMPH-1, TRIUMPH-4, and TRANSCEND-T2D-1). More Phase 3 readouts are expected in 2026. The earliest likely FDA filing is late 2026 or 2027, with potential approval in 2027.
Ozempic is available now. Retatrutide is not.
Should You Wait for Retatrutide?
No. If you need weight management help now, do not pause or delay current treatment for a drug you cannot get yet. Ozempic, Wegovy, Mounjaro, and Zepbound are all available and effective. Talk to your doctor about the best option for you today. If retatrutide becomes available later, you and your doctor can discuss switching then.
See our retatrutide guide for full pipeline details, and Mounjaro vs Retatrutide for the most recently updated comparison page in this cluster.
Cost
No pricing yet for Retatrutide. Likely similar to other Eli Lilly GLP-1 medications (~$1,060/month). Ozempic pricing varies by insurance — see our Ozempic/Wegovy/Rybelsus guide.
FAQ
When will retatrutide be approved by the FDA?
Retatrutide is not yet FDA-approved. As of May 2026, three Phase 3 trials have reported positive results, with more Phase 3 readouts expected in 2026. The earliest likely FDA filing is late 2026 or 2027, with potential approval in 2027.
Is retatrutide better than Ozempic for weight loss?
TRIUMPH-1 showed retatrutide produced up to 28.3% body weight loss at 80 weeks compared to approximately 10–15% for Ozempic in separate trials. Early data suggests a significant advantage, but retatrutide is not yet approved and no direct head-to-head comparison exists.
Why does retatrutide cause increased heart rate?
Retatrutide includes a glucagon receptor agonist component. Glucagon increases metabolic rate and energy expenditure, which can also raise heart rate slightly. This side effect is being monitored closely in ongoing Phase 3 trials.
Should I wait for retatrutide instead of starting Ozempic?
No. Retatrutide will not be available until at least 2027. If you need weight management help now, Ozempic and other approved GLP-1 medications are available and effective. Talk to your doctor about the best current option for you.
Bottom Line
Ozempic is available now and works well for millions of people. Retatrutide shows stronger weight loss in Phase 3 trials — up to 28.3% at 80 weeks (TRIUMPH-1) vs 10–15% for Ozempic — but it is not FDA-approved and not available. The earliest possible approval is likely 2027. If Ozempic is working for you, there is no reason to wait. If you are not getting the results you want, talk to your doctor about current options like tirzepatide (Mounjaro/Zepbound).
Work with your healthcare provider to determine which medication is right for you. Individual results and experiences vary.
